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Background and Introduction
Exposure to chemicals contained in products such as perfumes, household cleaners, and petroleum-based products has been considered safe and often pleasant. However, reports of unusual sensitivity and illness in response to such items have increased. For example, in the occupational literature, Schottenfeld and Cullen (1) first described a group of patients who became ill following exposure and who later developed medically unexplained symptoms triggered by events (e.g., exposure to odors such as perfumes) that reminded them of their exposure-related illness. Schottenfeld and Cullen described this reaction as an anxiety response, i.e., typical and atypical posttraumatic stress disorder, rather than a heightened physiological sensitivity to chemicals. Several other investigators have suggested that sensitivity to low-level chemical exposures is the modern expression of well-known psychiatric disorders such as anxiety, depression, or somatization (2, 3) . A growing debate has arisen between those who regard chemical sensitivity as a disorder mediated by psychiatric factors in a manner similar to conditioned responses and those who see it as a genuine physical susceptibility to low-dose exposures presumed safe. In 1987, Cullen edited a state of the art review for occupational medicine on multiple chemical sensitivities (MCS) in which he suggested a case definition to promote commonality among cases. This definition also attempted to distinguish MCS, at least conceptually, from traditional occupational disease and psychiatric illness. The following components were proposed: initial symptoms acquired in relation to an identifiable environmental exposure(s); symptoms that involve more than one organ system; symptoms that recur and abate in response to predictable stimuli; symptoms elicited by low-level exposures to chemicals of diverse structural classes; and inability to explain symptoms by standard tests of organ-system function.
Decades prior to the recognition of MCS in the occupational health literature, clinical ecologists or environmental physicians suggested that exposure to levels of chemicals most of the population tolerates may produce symptoms and illness in susceptible individuals (4) . However, those physicians cast a much wider net to attribute many defined pathologic illnesses such as cancer, arthritis, and vasculitis to chemical exposures (5) . They invoked the general adaptation syndrome model of stress, proposed by Selye (6) (12) , initiating events were highly varied within and between subject groups (Table 3 ). In the Simon et al. study (9) , subjects were recruited from one aerospace manufacturing workplace in which worker compensation claims were being evaluated. Miller and Mitzel (12) , in a questionnaire study, included only subjects who could recall a specific organophosphate exposure or remodeling event after which chemical sensitivities developed. Subjects who could not recall one of these events at a specific time were not included. Unlike the majority of studies cited above, subjects in a study by Simon et al. (9) were identified from worker's compensation cases following an outbreak of illness among a group of plastics workers from the aerospace industry. Therefore, it was assumed that these workers (n = 13) all had a similar initiating exposure. The authors reported that complaints of symptoms occurred in response to the introduction of a new composite plastic material into the manufacturing process. The principal components of this material were phenol, formaldehyde, and methyl ethyl ketone (MEK). Exposure measurements did not find levels that approached established thresholds.
Explicit in the varying definitions of chemical sensitivities is the concept that multiple chemicals at low levels produce symptoms. Kipen et al. (14) , using a modified version of the Randolph environmental questionnaire, found that chemically sensitive subjects reported significantly more substances that made them ill than did either healthy or sick controls ( Figure  1 ). Women reported more substances than men, independent of health status.
While most investigators imply that chemically sensitive patients have symptoms representative of multiple physiologic systems, not all reported on the organ systems or symptoms. Table 4 gives a sample of the percentage of subjects reporting symptoms in each organ system (2, 8, 10 
---0 10 (43) DIS, diagnostic interview schedule. (9, 16) , and on the Barsky Amplification Scale, a scale associated with somatic symptoms (9) . In composite, MCS subjects relative to controls tend to report a higher number of physical symptoms and score higher on scales that reflect concerns with somatic sensations. Preliminary data from our current study also support sensitivity in response to the physical sensations of anxiety (Figure 3) . (19) reported that more chemically sensitive ("universal reactors") and psychologic subjects were classified as having higher EEG 5-activity during relaxation than controls. Chemically sensitive subjects also had higher levels of electromylogram (EMG) scalp activity than either normal or psychologic subjects. No differences were observed between the groups for peripheral temperature or skin resistance while relaxing. The authors report these findings in support of the psychosomatic-hypothesis of intolerance to environmental chemicals. Both the psychologic and MCS groups included a wide range of psychologic disorder (e.g., multiple personality disorder, depression, panic). The authors reported that 50% of the MCS group, who were willing to accept psychologic intervention, had various psychiatric diagnoses, but the diagnoses were not given. This information suggests that the only difference between the psychologic and the MCS groups was the attribution of illness to chemicals or environmental exposures. Thus, the similarities found between the groups were not surprising.
While other investigators, e.g., Rea (20) , have reported the use of SPECT and PET for evaluation of chemically sensitive patients, no controlled studies have yet appeared in the literature.
Controlled Challenges
Environmental physicians or clinical ecologists and Selner and Staudenmayer (21) have reported controlled challenge studies of chemically sensitive or environmentally allergic patients. These investigators use the word control to describe the use of masking and placebos. However, no study has appeared in the literature in which normal controls, matched on appropriate demographic variables, have also been challenged or exposed under the identical protocol. Such controlled studies are sorely needed and their design is the subject of the present workshop.
Nasal Pathology and Olfaction
MCS patients often report heightened odor sensitivity (10) . Researchers have conceptualized that this sensitivity would be expressed in reduced odor threshold. Doty (4, 24, 25) . Antichemical (e.g., formaldehyde) antibodies have been reported (26) (27) (28) , as have elevated levels of autoantibodies (29) . Changes in lymphocyte subsets have been reported (25) (26) (27) (28) (29) (30) . The preliminary description of T-cell subset abnormalities reported by Kipen et al. (25) , have not been confirmed with testing of increased numbers of patients and inclusion of healthy controls (31) . Elevated frequencies of activated lymphocytes are also described (27) (28) (29) . Terr published on a case series of 50 worker's compensation patients and reported no abnormality of immunoglobulin, B-cell, and T-cell subset levels (13) . Pathologic inflammatory changes in the nose have also been described (32) , and neurogenic inflammatory processes in the nose have been proposed as a pathogenic mechanism for MCS (33) . Simon et al. (15) published the one carefully controlled and laboratory blinded case comparison study of subjects with chemical sensitivity (Table 8 ). Compared to subjects with musculoskeletal problems, tests for four autoantibodies, B-cells, and T-cell subsets showed no significant differences between the two groups. Tests for one autoantibody and two tests of immune cell activation (TAl cell percentage and interleukin-1 [IL-1] generation) showed higher levels in the musculoskeletal group. Many values for individuals in both groups were abnormal according to laboratory reference ranges. Subsequent correspondence criticized the reported methods for both the antibody determinations and the determination of lymphocyte markers (34) . Subsequently, the authors of this negative study disclosed that on a limited number of split samples, the reliability of the laboratory was little better than chance (35 
Summary and Conclusions
Controversy has surrounded the process for selecting or distinguishing patients who have chemical sensitivity. That is, investigators and clinicians such as Rea (36) and Ross (37) include patients with diverse medical conditions as among those suffering from chemical sensitivities. Thus, their patient groups are highly heterogeneous while more recent investigators, using Cullen's definition (7), have attempted to reduce this hetergeneity by excluding other medical illnesses (10, 15, 38) . Understanding the characteristics of the subjects under study is crucial to understanding the phenomenon of chemical sensitivity. Therefore, in future studies investigators may want to include patients with other diagnoses; subjects should be stratified by diagnostic category and analyzed distinctly from subjects whose primary clinical characteristic is sensitivity to low-level chemical exposure. Cross-sectional comparisons of MCS subjects have not revealed any consistent cognitive or immunologic pathology among patients whose primary clinical characterization is chemical sensitivity. Even among this potentially more homogeneous group, however, subjects suffer from a range of recognized psychiatric disorders, including depression and anxiety. In fact, the most consistent finding among studies to date is that of a higher rate of any psychiatric disorder. Since no prospective studies have yet been undertaken, causality cannot be implied from these findings. Case definitions such as the one suggested by Cullen (7) may offer a false sense of homogeneity among patients. That is, at this stage of our understanding, it remains important to look carefully at individual data from subjects, since they may tell us more about the manifestations of this disorder than group comparisons when the groups are by necessity poorly defined. Finally, the crucial point that has yet to be addressed is the relationship between low-level chemical exposures and symptoms/objective illness reported by chemically sensitive patients. Whatever the causality, demonstrating a relationship between chemical exposure at the levels reported clinically and symptoms in a carefully defined set of patients is a necessary first step in determining whether chemical sensitivity represents an illness that requires a new model such as that described by Miller (39) .
